Patients undergoing total hip arthroplasty using a combination of paracetamol, ibuprofen, and dexamethasone, had optimal responses with the lowest morphine consumption, and fewer adverse events.
Read Article
A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.
A metanalysis was performed using databases, trial
A metanalysis shows that social determinants of health adversely impacts patients with lupus nephritis. Lupus nephritis is a significant complication of SLE, often with dramatic increases in morbid and mortal risks. Outcomes are likely to be augmented by social determinants of health, including
Read Article
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush muses on the news, journal reports, FDA announcements and the 2024 BSR abstracts just released.
Read Article
A cohort analysis of dermatomyositis (DM) patients starting immunomodulators finds that methotrexate use was not associated with an increased risk of interstitial lung disease (ILD).
ILD affects ~23% of DM patients and the oft used MTX is has a low risk of pneumonitis and pulmonary
Read Article
In an open-label, randomized, non-inferiority trial, rheumatoid arthritis patients in remission were subject to tapering of disease-modifying antirheumatic drugs (DMARDs), and while maintenance of remission was seen in some, many DMARD tapering patients did flare and were unable to maintain
Read Article
An investigational Toll-like receptor (TLR) antagonist was effective in reducing biomarkers and clinical symptoms of systemic lupus erythematosus (SLE) in a pilot trial, evidence that the innate immune system may hold the key to lupus pathophysiology.
Read Article
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews this past week’s news and journal articles from RheumNow.com.
Read Article
An observational cohort study suggests that proteinuria levels in lupus nephritis (LN) patients did not predict their histologic class.
A multicentre observational study of patients with biopsy-proven LN; either proliferative (PLN) or membranous (MLN) lupus nephritis were compared regarding
Dr. John Cush @RheumNow( View Tweet )
Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.
Read Article
A population-based cohort has demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) use in gout patients is superior to sulfonylurea therapy in lowering the risk of incident gout and recurrent flares among patients with type 2 diabetes (T2D).
Read Article
Links:
Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.
Read Article
The management and outcomes of neuropsychiatric systemic lupus erythematosus (NPSLE) can be challenging as there is limited data.
A retrospective cohort study identified 350 NPSLE events (between 1999-2015) defined by ACR definitions and categorized as being:
Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.
Read Article
It is a common clinical scenario to see someone with both severe psoriatic arthritis and skin psoriasis. In an ideal world this would involve a combined clinic with our local friendly dermatologist. For many of us, however, this is not practical for many reasons. The excellent Saturday morning
Read Article
